Compounded Semaglutide Providers in 2026 — Ranked & Reviewed
Compounded semaglutide is a low-cost alternative to brand-name Wegovy and Ozempic, made by 503A and 503B pharmacies under physician supervision. We ranked the most reputable telehealth clinics offering compounded semaglutide in 2026 by price, pharmacy verification, clinical care, and shipping. Every provider on this list ships nationwide.
Lowest verified price: $25/mo339 providers compared
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
339 compounded semaglutide providers compared · independently scored against our six-factor methodology.
Compare the top providers at a glance
Logos, our editorial rating, price, medications, and coverage — the fastest way to narrow the list.
- ★ Editor's Pick
mainstream telehealth GLP-1 access
From /mo$99Coverage50 statesMedicationsSemaglutideTirzepatide lab-monitored compounded GLP-1 with mandatory video visit
From /mo$112Flat at every doseCoverage39 statesMedicationsSemaglutideTirzepatide- Nationwide Coverage
compounded GLP-1/GIP combo therapy on a yearly subscription with free shipping nationwide
From /mo$129Flat at every doseCoverage50 statesMedicationsSemaglutideTirzepatide mainstream telehealth GLP-1 access
From /mo$99Flat at every doseCoverage50 statesMedicationsSemaglutideTirzepatide- Transparent Pricing
shoppers wanting physician-led, pharmacy-transparent compounded GLP-1 with brand-name options
From /mo$179Coverage50 statesMedicationsSemaglutideTirzepatide - Best Budget
budget-conscious shoppers
From /mo$93CoverageCheck intakeMedicationsSemaglutideTirzepatide compounded semaglutide and tirzepatide at a flat monthly price
From /mo$119Flat at every doseCoverageCheck intakeMedicationsSemaglutideTirzepatidemainstream telehealth GLP-1 access
From /mo$149CoverageCheck intakeMedicationsSemaglutideTirzepatideOrforglipron
| Provider | Rating | From /mo | Medications | Coverage | |
|---|---|---|---|---|---|
★ Editor's Pick mainstream telehealth GLP-1 access | $99 | SemaglutideTirzepatide | 50 states | Visit → | |
 lab-monitored compounded GLP-1 with mandatory video visit | $112 Flat pricing | SemaglutideTirzepatide | 39 states | Visit → | |
Nationwide Coverage compounded GLP-1/GIP combo therapy on a yearly subscription with free shipping nationwide | $129 Flat pricing | SemaglutideTirzepatide | 50 states | Visit → | |
 mainstream telehealth GLP-1 access | $99 Flat pricing | SemaglutideTirzepatide | 50 states | Visit → | |
Transparent Pricing shoppers wanting physician-led, pharmacy-transparent compounded GLP-1 with brand-name options | $179 | SemaglutideTirzepatide | 50 states | Visit → | |
Best Budget budget-conscious shoppers | $93 | SemaglutideTirzepatide | Check intake | Visit → | |
 compounded semaglutide and tirzepatide at a flat monthly price | $119 Flat pricing | SemaglutideTirzepatide | Check intake | Visit → | |
 mainstream telehealth GLP-1 access | $149 | SemaglutideTirzepatideOrforglipron | Check intake | Visit → |
Providers that don’t post pricing up front score lower on Value and carry a cost-transparency note in their review. Read the full methodology →
Detailed Reviews
Found
Verified partnerBest for: mainstream telehealth GLP-1 access
Personalized weight care platform with a self-pay membership model plus medication costs.
Score Breakdown
Pros
- ✓Aggressively low monthly pricing
- ✓Both semaglutide and tirzepatide available
- ✓Compounded GLP-1 access
Cons
- ✗Limited public information on program details
Enhance MD
Verified partnerBest for: lab-monitored compounded GLP-1 with mandatory video visit
Enhance MD pairs compounded semaglutide and tirzepatide with mandatory baseline metabolic labs at Quest Diagnostics and a synchronous video visit with a board-certified clinician — a more rigorous onboarding than the async-only compounded GLP-1 model most telehealth providers use. Three tiers (Core semaglutide, Advanced tirzepatide, Elite combined) plus $100-off-first-order intro pricing ($112 first month on Core with code SUMMER100).
Score Breakdown
Pros
- ✓Baseline and ongoing metabolic labs (CMP, lipids, TSH, HbA1c) at Quest every 6 months — rare for compounded GLP-1
- ✓Mandatory video visit with a US-licensed MD or NP before your first prescription — not a pure questionnaire model
- ✓Three tiers, including a combined semaglutide + tirzepatide Elite plan ($322/mo) for patients plateaued on one GLP-1
- ✓Uses LegitScript-certified 503A pharmacies (Tru Meds Rx, Strive Pharmacy, Pharmacy Hub)
- ✓Intro pricing via $100 off your first order (code SUMMER100): $112 Core, $180 Advanced, $222 Elite first month
- ✓Unlimited clinician messaging and dose-adjustment support included
Cons
- ✗Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro
- ✗Not available in 10 states: AL, AR, GA, HI, LA, MS, MO, SC, TN, WV
- ✗Mandatory lab work adds 5–10 days to onboarding vs async-only competitors
- ✗No insurance accepted — cash pay, HSA/FSA eligible
- ✗Intro discount applies only to the first order — ongoing rates are $212–$322/mo on 12-month plans, or $249–$379/mo month-to-month
Gala
Verified partnerBest for: compounded GLP-1/GIP combo therapy on a yearly subscription with free shipping nationwide
Gala (legal entity AI Coaching Inc., d/b/a Gala GLP-1) is a Delaware-incorporated telehealth platform offering compounded semaglutide and compounded tirzepatide on a yearly subscription, a lower-priced microdosing program, and brand-name Ozempic. The marketing site claims licensed providers in all 50 states with free shipping included. An oral Wegovy pill option is listed as 'coming soon.'
Score Breakdown
Pros
- ✓Compounded semaglutide and tirzepatide at $179/mo with all doses included on the yearly plan
- ✓Lower microdosing tirzepatide tier at $149/mo for a sub-therapeutic starting protocol
- ✓Brand-name Ozempic available alongside compounded options
- ✓Claims licensed providers in all 50 states with free shipping included
- ✓24/7 support, provider visit included, cancel anytime
- ✓LegitScript verified
Cons
- ✗$179/mo requires a yearly subscription — the standalone monthly price isn't published
- ✗Brand-name Ozempic at $1,299/mo is higher than peers (e.g., Found at $1,100/mo)
- ✗Pharmacy partners not named — only a "network of pharmacies" reference
- ✗Wegovy oral pill listed as "coming soon," not yet available
- ✗Per-state availability isn't listed; the all-50-states claim is gated behind intake
bmiMD
Verified partnerBest for: mainstream telehealth GLP-1 access
Medical weight loss clinic offering GLP-1 prescriptions through telehealth.
Score Breakdown
Pros
- ✓Both semaglutide and tirzepatide available
Cons
- ✗Pricing not publicly disclosed
RxSpan MD
Verified partnerBest for: shoppers wanting physician-led, pharmacy-transparent compounded GLP-1 with brand-name options
RxSpan MD is a physician-led telehealth practice founded by Dr. John Diaz, a board-certified plastic surgeon, offering compounded GLP-1 weight loss — semaglutide and tirzepatide from $249/mo, as injections or oral capsules — plus brand-name Wegovy, Zepbound and Ozempic. It's unusually transparent: it names its 503A pharmacy partners (Belmar, Strive, Epiq Scripts, Casa Pharma) and medical group, ships free, and includes unlimited 24/7 support. Available in all 50 states.
Score Breakdown
Pros
- ✓Physician-led — founded by Dr. John Diaz, a board-certified plastic surgeon with 20+ years' experience
- ✓Compounded semaglutide and tirzepatide from $249/mo (injection or oral capsules), plus brand-name Wegovy, Zepbound and Ozempic
- ✓Names its 503A pharmacy partners (Belmar, Strive, Epiq Scripts, Casa Pharma) and medical group
- ✓LegitScript-certified (#50405601); free expedited shipping and unlimited 24/7 support included
- ✓Available in all 50 states via a 2-minute assessment
Cons
- ✗Compounded pricing ($249 semaglutide / $329 tirzepatide) sits mid-to-high versus the cheapest telehealth options
- ✗Brand-name GLP-1 is priced steeply (Wegovy $1,349, Ozempic $1,299, Zepbound $1,069)
- ✗Multi-vertical practice (also hair, sexual health, longevity), not weight-loss-only
- ✗Legal entity name isn't published on the site
How to choose a compounded semaglutide provider
Compounded semaglutide is a lower-cost alternative to Wegovy and Ozempic, made by 503A/503B pharmacies. It uses the same active ingredient, but it is not FDA-approved, so the pharmacy behind it is everything.
What to look for
- 503A or 503B pharmacy, named. The provider should name its compounding pharmacy and its accreditation. Unnamed 'US-based pharmacy partners' with no detail is a transparency gap.
- Injectable over oral. Injectable compounded semaglutide mirrors the studied product. Oral/sublingual compounded versions have far weaker absorption evidence — treat bold oral claims with caution.
- No surprise additives. Some pharmacies add B6/B12 or other agents. That's not inherently bad, but you should know exactly what's in the vial before you start.
Red flags to avoid
- No named pharmacy or LegitScript listing. A legitimate compounded-GLP-1 provider names its 503A/503B pharmacy partner and carries LegitScript certification. If neither is disclosed, you can't verify what you're injecting.
- Async-only, no real clinician review. A prescriber should review your intake and be reachable for dose questions. Instant approval with no way to reach a clinician is a safety gap.
- Teaser pricing that hides the real cost. A low 'first month' price that jumps at higher doses, or a membership fee stacked on top of the medication, can double the true monthly total. Confirm the ongoing, all-in price before you pay.
- Weight-loss claims for B12, MIC, or HCG shots. Only GLP-1 injections have trial evidence for weight loss. A clinic selling B12, lipotropic, or HCG shots as a weight-loss treatment is a red flag.
Every provider ranked above is scored against these criteria across our six-dimension methodology, and prices are re-verified against each provider’s live site.
How we rank & what counts as “legit”
Every provider in this ranking is scored against our published six-factor rubric[1] — value, effectiveness, user experience, trust & safety, accessibility, and support. Compounded GLP-1s from licensed 503A and 503B pharmacies are legal under federal compounding law[2], with additional tolerances historically allowed while semaglutide and tirzepatide were on the FDA Drug Shortage List[3].
Brand-name Wegovy, Zepbound, Ozempic, and Mounjaro are separately FDA-approved under their own NDA numbers[4][5]. Published Phase 3 efficacy for semaglutide 2.4 mg (~14.9% mean weight loss over 68 weeks) comes from the STEP 1 trial[6], and for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) from SURMOUNT-1[7]; the SURMOUNT-5 head-to-head published in 2025 compared the two directly[8].
Insurance coverage for anti-obesity medications varies widely by state Medicaid program and commercial plan[9][10]. Compounded and brand-name GLP-1s are generally FSA/HSA eligible with a prescription under IRS Publication 502[11].
Frequently Asked Questions
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Semaglutide · Drugs and brands
- Wegovy · Drugs and brands
- Ozempic · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- 503B outsourcing facility · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- FDA Drug Shortage List · Insurance and regulatory
Sources & methodology — as of July 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
- 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
- 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.